8-K: Rani Therapeutics Faces Nasdaq Delisting Risk

Rani Therapeutics Holdings, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, though it has been granted an extension to regain compliance.

Summary

• Rani Therapeutics Holdings, Inc. (the Company) received a notice from The Nasdaq Stock Market LLC (Nasdaq) on November 10, 2026, indicating non-compliance with the minimum closing bid price requirement of $1.00 per share.
• The Company was initially given 180 days, until November 9, 2026, to regain compliance.
• Nasdaq has approved the Company's application to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 12, 2026.
• The Company has been granted an additional 180 calendar days, until May 10, 2027, to regain compliance with the Minimum Bid Price Requirement.
• To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the extended period.
• Nasdaq may require a longer compliance period (up to 20 consecutive business days) at its discretion.
• The Company intends to monitor its stock price and evaluate options to regain compliance, which may include a reverse stock split.
• There is no assurance that the Company will regain compliance or maintain other listing requirements.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the company is at risk of delisting from Nasdaq due to its low stock price, despite being granted an extension.

Positives

• The Company successfully applied to transfer its listing to The Nasdaq Capital Market, which offers an extended compliance period.
• The Company met the applicable market value of publicly held shares requirement and other initial listing requirements for The Nasdaq Capital Market.
• The Company has been granted an additional 180 days to regain compliance with the minimum bid price requirement.

Negatives

• The Company's Class A common stock has failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
• The Company is at risk of delisting from Nasdaq if it cannot regain compliance with the minimum bid price requirement by May 10, 2027.
• There is no guarantee that the Company will be able to regain compliance within the extended period.

Risks

• Failure to regain compliance with the Minimum Bid Price Requirement by May 10, 2027, could lead to the delisting of the Company's Class A common stock from The Nasdaq Capital Market.
• Nasdaq may require a longer compliance period (up to 20 consecutive business days) at its discretion.
• There is no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or maintain compliance with other continued listing requirements.

Future Outlook

The Company intends to actively monitor the closing bid price of its Class A common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement, which may include a reverse stock split. However, there can be no assurance of success.

Management Comments

• The Company intends to actively monitor the closing bid price of its Class A common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement.
• There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional compliance period or otherwise maintain compliance with the other continued listing requirements of The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that maintaining a minimum stock price is a common requirement for major exchanges like Nasdaq. Companies facing such issues often explore options like reverse stock splits to meet these thresholds, though this can sometimes be viewed negatively by investors.

Stakeholder Impact

• Shareholders: Risk of delisting from Nasdaq, which could negatively impact liquidity and stock value. Potential dilution if a reverse stock split is implemented without a corresponding increase in market capitalization.
• Creditors: Potential concerns about the company's financial stability and ability to meet obligations if delisting occurs.

Next Steps

• Actively monitor the closing bid price of Class A common stock.
• Evaluate available options to regain compliance with the Minimum Bid Price Requirement.
• Potentially effect a reverse stock split if necessary.

Key Dates

Recommendation

The filing indicates a significant risk of delisting due to failure to meet the minimum bid price requirement. While an extension has been granted and a transfer to the Nasdaq Capital Market has occurred, the underlying issue remains unresolved. Investors should hold positions cautiously, awaiting clear evidence of the company's ability to regain compliance and improve its stock performance. The potential for a reverse stock split introduces further uncertainty.

Keywords

Nasdaq Listing, Minimum Bid Price, Delisting Risk, Compliance Period, Stock Price, Capital Market, Reverse Stock Split